Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chronotherapy GP induction plus concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma
ChiCTR2400086032Phase 3Not yet recruiting
- Sponsor
- Tumor Hospital Affiliated to Guizhou Medical University
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Tumor Hospital Affiliated to Guizhou Medical University. Primary endpoints: 3-year recurrence-free survival rate, Overall survival and 1 more. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2400086032.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400086032.